No Data
No Data
Kainos Laboratories FY Parent Net Y637.00M Vs Net Y568.00M
Kainos Laboratories Inc. (4556.TO) Japan Year Ended March 31 PARENT 2024 2023 Revenue Y5.06 bln Y4.92 bln Operating Profit Y865.00 mln Y
Kainos Laboratories Sees FY Net Y550.00M
Kainos Laboratories Inc. also released the following forecasts: PARENT 1st Half To Year Ending Sep 2024 Mar 2025 Revenue Y2.65 bln Y5.40 b
KAINOS LABORATORIES: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (unconsolidated)
Kirin HD, Takeda Pharmaceutical, Sumitomo, SoftBank (9th)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/9 (Thu) <1375>Snow Country Maitake <1720>Tokyu Construction<1738>Nittoh <1764>Kudo Construction<1788>Santo Kogyo <1799>Daiichi Kenset<1869>Meikouken <1870>Yahagi Kenset<1929
NISSUI, AXAS HOLDINGS, etc.
<1332>Nissui Nomura Securities Co., Ltd. Stock holding ratio 10.71% → 9.78% reporting obligation date 2024/04/10 <3193>Tori Kizoku Holdings Co., Ltd. Okura Chuji share holding ratio 33.73% → 32.30% reporting obligation occurrence date 2024/04/05 <3260>Espoir J Trust Co., Ltd. Stock holding ratio 8.09% → 6.96% reporting obligation date 2024
Kainos Laboratories Raises FY Dividend Plan to Y32.00
Kainos Laboratories Inc. (4556.TO) PARENT Latest Revision Previous For Year to Mar 2024 Plan Year-end Y32.00 Y25.00 Annual Y32.00
No Data